JP2017501140A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017501140A5 JP2017501140A5 JP2016536248A JP2016536248A JP2017501140A5 JP 2017501140 A5 JP2017501140 A5 JP 2017501140A5 JP 2016536248 A JP2016536248 A JP 2016536248A JP 2016536248 A JP2016536248 A JP 2016536248A JP 2017501140 A5 JP2017501140 A5 JP 2017501140A5
- Authority
- JP
- Japan
- Prior art keywords
- cgvhd
- day
- cell transplantation
- ibrutinib
- medicament according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000003814 drug Substances 0.000 claims 16
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 claims 6
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 claims 5
- 229960001507 ibrutinib Drugs 0.000 claims 5
- 238000002054 transplantation Methods 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 3
- 206010006448 Bronchiolitis Diseases 0.000 claims 2
- 206010039710 Scleroderma Diseases 0.000 claims 2
- 230000000735 allogeneic effect Effects 0.000 claims 2
- 238000010322 bone marrow transplantation Methods 0.000 claims 2
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 claims 2
- 230000000414 obstructive effect Effects 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 208000017760 chronic graft versus host disease Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Claims (16)
- （Ｒ）−１−（３−（４−アミノ−３−（４−フェノキシフェニル）−１Ｈ−ピラゾロ［３，４−ｄ］ピリミジン−１−イル）ピペリジン−１−イル）プロプ−２−エン−１−オン（イブルチニブ）を含む、同種抗体により駆動される慢性移植片対宿主病（ｃＧＶＨＤ）の処置のための医薬、又はその薬学的に許容可能な塩。
- ｃＧＶＨＤは非硬皮症のｃＧＶＨＤである、ことを特徴とする請求項１に記載の医薬。
- ｃＧＶＨＤは多臓器のｃＧＶＨＤである、ことを特徴とする請求項１に記載の医薬。
- ｃＧＶＨＤは閉塞性細気管支炎症候群である、ことを特徴とする請求項１に記載の医薬。
- ｃＧＶＨＤは肺のｃＧＶＨＤである、ことを特徴とする請求項１に記載の医薬。
- ｃＧＶＨＤは非硬皮症のｃＧＶＨＤまたは閉塞性細気管支炎症候群である、ことを特徴とする請求項１に記載の医薬。
- 線維症が減少される、ことを特徴とする請求項１乃至６の何れか１つに記載の医薬。
- 患者は細胞移植を受けたことがある、ことを特徴とする請求項１乃至７の何れか１つに記載の医薬。
- 細胞移植は造血細胞移植である、ことを特徴とする請求項８に記載の医薬。
- 細胞移植は同種異系骨髄又は造血幹細胞の移植である、ことを特徴とする請求項８に記載の医薬。
- イブルチニブは、同種異系骨髄又は造血幹細胞の移植と同時に投与される、ことを特徴とする請求項８に記載の医薬。
- 患者は再発性又は難治性のＣＬＬを患っている、ことを特徴とする請求項１乃至１１の何れか１つに記載の医薬。
- イブルチニブは、１日約０．１ｍｇ／ｋｇ乃至１日約１００ｍｇ／ｋｇの間の投与量に相当する量である、ことを特徴とする請求項１乃至１２の何れか１つに記載の医薬。
- イブルチニブは、約４０ｍｇ／日、約１４０ｍｇ／日、約４２０ｍｇ／日、約５６０ｍｇ／日、又は約８４０ｍｇ／日の量である、ことを特徴とする請求項１乃至１３の何れか１つに記載の医薬。
- イブルチニブは経口投与に適している、ことを特徴とする請求項１乃至１４の何れか１つに記載の医薬。
- イブルチニブは、１以上の付加的な治療剤と組み合わせて投与される、ことを特徴とする請求項１乃至１５の何れか１つに記載の医薬。
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361910944P | 2013-12-02 | 2013-12-02 | |
| US61/910,944 | 2013-12-02 | ||
| US201461973178P | 2014-03-31 | 2014-03-31 | |
| US61/973,178 | 2014-03-31 | ||
| PCT/US2014/068177 WO2015084857A1 (en) | 2013-12-02 | 2014-12-02 | Methods of treating and preventing alloantibody driven chronic graft versus host disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020025682A Division JP2020105181A (ja) | 2013-12-02 | 2020-02-18 | 同種抗体により駆動される慢性移植片対宿主病を処置及び予防する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017501140A JP2017501140A (ja) | 2017-01-12 |
| JP2017501140A5 true JP2017501140A5 (ja) | 2018-01-25 |
Family
ID=53270044
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016536248A Ceased JP2017501140A (ja) | 2013-12-02 | 2014-12-02 | 同種抗体により駆動される慢性移植片対宿主病を処置及び予防する方法 |
| JP2020025682A Ceased JP2020105181A (ja) | 2013-12-02 | 2020-02-18 | 同種抗体により駆動される慢性移植片対宿主病を処置及び予防する方法 |
| JP2022188655A Ceased JP2023029899A (ja) | 2013-12-02 | 2022-11-25 | 同種抗体により駆動される慢性移植片対宿主病を処置及び予防する方法 |
| JP2024010504A Pending JP2024072291A (ja) | 2013-12-02 | 2024-01-26 | 同種抗体により駆動される慢性移植片対宿主病を処置及び予防する方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020025682A Ceased JP2020105181A (ja) | 2013-12-02 | 2020-02-18 | 同種抗体により駆動される慢性移植片対宿主病を処置及び予防する方法 |
| JP2022188655A Ceased JP2023029899A (ja) | 2013-12-02 | 2022-11-25 | 同種抗体により駆動される慢性移植片対宿主病を処置及び予防する方法 |
| JP2024010504A Pending JP2024072291A (ja) | 2013-12-02 | 2024-01-26 | 同種抗体により駆動される慢性移植片対宿主病を処置及び予防する方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US20150157634A1 (ja) |
| EP (1) | EP3076975A4 (ja) |
| JP (4) | JP2017501140A (ja) |
| KR (2) | KR20160085817A (ja) |
| CN (2) | CN105939717B (ja) |
| AU (3) | AU2014360758B2 (ja) |
| BR (1) | BR112016012158A2 (ja) |
| CA (2) | CA2932255C (ja) |
| EA (1) | EA201691020A1 (ja) |
| IL (3) | IL292522A (ja) |
| MX (2) | MX2016006955A (ja) |
| PH (1) | PH12016501051A1 (ja) |
| TW (3) | TW202228700A (ja) |
| WO (1) | WO2015084857A1 (ja) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI662964B (zh) | 2012-06-04 | 2019-06-21 | 美商製藥有限責任公司 | 布魯頓氏酪胺酸激酶抑制劑之結晶形式 |
| TWI620565B (zh) * | 2013-10-25 | 2018-04-11 | 製藥公司 | 治療及預防移植物抗宿主病之方法 |
| AR102871A1 (es) | 2014-12-03 | 2017-03-29 | Pharmacyclics Llc | Métodos de tratamiento de fibrosis |
| US20190070145A1 (en) * | 2016-03-22 | 2019-03-07 | Mayo Foundation For Medical Education And Research | Using fatty acid synthase inhibitors to treat fibrosis |
| WO2018002958A1 (en) * | 2016-06-30 | 2018-01-04 | Sun Pharma Advanced Research Company Limited | Novel hydrazide containing compounds as btk inhibitors |
| WO2018075888A1 (en) * | 2016-10-21 | 2018-04-26 | Regents Of The University Of Minnesota | Materials and methods for treating or preventing graft-versus-host-disease |
| CZ2017787A3 (cs) | 2017-12-08 | 2019-06-19 | Zentiva, K.S. | Farmaceutické kompozice obsahující ibrutinib |
| WO2021038540A1 (en) | 2019-08-31 | 2021-03-04 | Sun Pharma Advanced Research Company Limited | Cycloalkylidene carboxylic acids and derivatives as btk inhibitors |
| WO2022119931A1 (en) * | 2020-12-01 | 2022-06-09 | City Of Hope | Prevention and treatment of graft-versus-host disease (gvhd) |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060182723A1 (en) * | 2005-01-25 | 2006-08-17 | Spellberg Brad J | Methods for treating refractory infections in neutropenic individuals |
| CA2636696A1 (en) * | 2006-01-13 | 2007-08-02 | Pharmacyclics, Inc. | Inhibitors of tyrosine kinases and uses thereof |
| EP2201840B1 (en) * | 2006-09-22 | 2011-11-02 | Pharmacyclics, Inc. | Inhibitors of Bruton's Tyrosine Kinase |
| CN102159214A (zh) * | 2008-07-16 | 2011-08-17 | 药品循环公司 | 用于实体肿瘤的治疗的布鲁顿酪氨酸激酶的抑制剂 |
| JP5656976B2 (ja) * | 2009-04-29 | 2015-01-21 | ローカス ファーマシューティカルズ インコーポレイテッド | ピロロトリアジン化合物 |
| AU2010286361A1 (en) * | 2009-08-31 | 2012-03-15 | Amplimmune, Inc. | Methods and compositions for the inhibition of transplant rejection |
| US20120071497A1 (en) * | 2010-06-03 | 2012-03-22 | Pharmacyclics, Inc. | Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase |
| MY191929A (en) * | 2010-06-03 | 2022-07-18 | Pharmacyclics Llc | The use of inhibitors of bruton's tyrosine kinase (btk) |
| KR20140058543A (ko) * | 2011-07-08 | 2014-05-14 | 노파르티스 아게 | 신규 피롤로 피리미딘 유도체 |
| ES2681050T3 (es) * | 2012-04-11 | 2018-09-11 | Acerta Pharma B.V. | Inhibidores de la tirosina quinasa de Bruton para la movilización hematopoyética |
| WO2013177596A2 (en) * | 2012-05-25 | 2013-11-28 | Sloan Kettering Institute For Cancer | Methods for treating gi syndrome and graft versus host disease |
| CN104994875B (zh) * | 2013-02-15 | 2018-10-09 | 免疫医疗公司 | 嵌合和人源化抗组蛋白抗体 |
| TWI620565B (zh) * | 2013-10-25 | 2018-04-11 | 製藥公司 | 治療及預防移植物抗宿主病之方法 |
| TWI810588B (zh) * | 2015-03-03 | 2023-08-01 | 美商製藥公司 | 布魯東氏(bruton’s)酪胺酸激酶抑制劑之醫藥調配物 |
-
2014
- 2014-12-02 CA CA2932255A patent/CA2932255C/en active Active
- 2014-12-02 EA EA201691020A patent/EA201691020A1/ru unknown
- 2014-12-02 TW TW110135203A patent/TW202228700A/zh unknown
- 2014-12-02 CA CA3210338A patent/CA3210338A1/en active Pending
- 2014-12-02 KR KR1020167015178A patent/KR20160085817A/ko active IP Right Grant
- 2014-12-02 JP JP2016536248A patent/JP2017501140A/ja not_active Ceased
- 2014-12-02 AU AU2014360758A patent/AU2014360758B2/en active Active
- 2014-12-02 US US14/558,297 patent/US20150157634A1/en not_active Abandoned
- 2014-12-02 EP EP14867905.3A patent/EP3076975A4/en active Pending
- 2014-12-02 MX MX2016006955A patent/MX2016006955A/es unknown
- 2014-12-02 IL IL292522A patent/IL292522A/en unknown
- 2014-12-02 CN CN201480074674.4A patent/CN105939717B/zh active Active
- 2014-12-02 BR BR112016012158A patent/BR112016012158A2/pt not_active Application Discontinuation
- 2014-12-02 TW TW103141826A patent/TWI743019B/zh active
- 2014-12-02 CN CN201910760757.3A patent/CN110478353B/zh active Active
- 2014-12-02 TW TW112113060A patent/TW202402295A/zh unknown
- 2014-12-02 KR KR1020237021643A patent/KR20230104754A/ko not_active Application Discontinuation
- 2014-12-02 WO PCT/US2014/068177 patent/WO2015084857A1/en active Application Filing
-
2016
- 2016-05-18 IL IL245715A patent/IL245715A0/en unknown
- 2016-05-27 MX MX2022000209A patent/MX2022000209A/es unknown
- 2016-06-02 PH PH12016501051A patent/PH12016501051A1/en unknown
-
2017
- 2017-12-01 US US15/829,087 patent/US20180078558A1/en not_active Abandoned
-
2020
- 2020-02-18 JP JP2020025682A patent/JP2020105181A/ja not_active Ceased
- 2020-06-26 AU AU2020204276A patent/AU2020204276A1/en not_active Abandoned
- 2020-07-29 US US16/942,151 patent/US20210177854A1/en not_active Abandoned
- 2020-08-12 IL IL276683A patent/IL276683A/en unknown
-
2022
- 2022-04-29 US US17/733,419 patent/US20230100137A1/en not_active Abandoned
- 2022-06-02 AU AU2022203810A patent/AU2022203810A1/en active Pending
- 2022-11-25 JP JP2022188655A patent/JP2023029899A/ja not_active Ceased
-
2024
- 2024-01-26 JP JP2024010504A patent/JP2024072291A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017501140A5 (ja) | ||
| WO2014205229A8 (en) | Use of high dose pridopidine for treating huntington's disease | |
| JP2012532874A5 (ja) | ||
| WO2009043476A3 (en) | Neuromedin s as a therapeutic agent | |
| NZ625592A (en) | Compositions and methods for the treatment of hepatic diseases and disorders | |
| WO2009043505A3 (en) | Use of beta-melanotropin as a therapeutic agent, eg for the treatment of aids or alzheimer | |
| JP2016517888A5 (ja) | ||
| JP2012193216A5 (ja) | ||
| UY32599A (es) | Formulación oral sólida de abt-263 | |
| WO2009033711A3 (en) | Use of glp-1 as a therapeutic agent | |
| WO2009033733A3 (en) | Use of apeptide as a therapeutic agent | |
| WO2009039983A3 (en) | Use of a peptide as a therapeutic agent | |
| WO2009033739A3 (en) | Use of a peptide as a therapeutic agent | |
| WO2009033789A3 (en) | Use of a peptide as a therapeutic agent | |
| JP2015517489A5 (ja) | ||
| WO2009040048A3 (en) | Use of the c-reactive peptide as a therapeutic agent | |
| WO2009033764A3 (en) | Use of a peptide as a therapeutic agent | |
| JP2012517987A5 (ja) | 吸入用の医薬組成物のｆｐｄ特性を設定する方法 | |
| WO2009033730A3 (en) | Peptide gxgrgdspca as a therapeutic agent | |
| WO2009033757A3 (en) | Use of mage-3 antigen (271-279) as a therapeutic agent | |
| WO2009033723A3 (en) | Use of aip2 as a therapeutic agent | |
| WO2009033766A3 (en) | Use of a peptide as a therapeutic agent | |
| JP2014503593A5 (ja) | ||
| WO2009033787A3 (en) | Use of a peptide as a therapeutic agent | |
| JP2019535760A5 (ja) | ガボキサドールを用いた注意欠陥多動性障害（ａｄｈｄ）の治療方法 |